drugset / Trial / NCT01220817

Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study

NCT01220817

Phase 2 Completed 104 enrolled POM Wonderful LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

When given to men with recurrent prostate cancer, the investigators hypothesize that POMx is effective in slowing the rise of PSA as measured by PSA doubling time in men following initial therapy for prostate cancer. Further, the investigators believe that POMx will be shown to be safe and well tolerated.

Timeline

Start
2007-10
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject POMx Unknown 1 g
Subject POMx Unknown 3 g

Indications